|
|
Volumn 40, Issue 4, 2013, Pages 419-420
|
|
Biology and treatment of advanced renal cell carcinoma: A global perspective
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL MARKER;
HYPOXIA INDUCIBLE FACTOR;
MAMMALIAN TARGET OF RAPAMYCIN;
VASCULOTROPIN;
VON HIPPEL LINDAU PROTEIN;
ADVANCED CANCER;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER SURVIVAL;
CROSS RESISTANCE;
CYTOREDUCTIVE SURGERY;
EDITORIAL;
GENE MUTATION;
HUMAN;
KIDNEY CARCINOMA;
LIFE EXPECTANCY;
METASTASIS RESECTION;
MOLECULARLY TARGETED THERAPY;
NEPHRECTOMY;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
TREATMENT RESPONSE;
CARCINOMA, RENAL CELL;
HUMANS;
KIDNEY NEOPLASMS;
PERIODICALS AS TOPIC;
|
|
EID: 84883189197
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: 10.1053/j.seminoncol.2013.05.003 Document Type: Editorial |
|
Times cited : (2)
|
|
References (0)
|